|
| Tuesday, 20 September 2022, 23:50 HKT/SGT | |
| |
|
|
|
Gaithersburg, MD, USA and Suzhou BioBay, China, Sept 20, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead(TM) platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.
Presentation Details
Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer
Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics
Time/Date: 15:20 GMT on Wednesday, September 21, 2022
Presentation Topics:
-- Creating novel siRNA constructs for cancer treatment
-- Introduction to Sirnaomics' polypeptide nanoparticle delivery system (PNP-IT)
-- Introduction to STP705, Sirnaomics' lead oncology siRNA therapeutic targeting TGF-beta1/COX-2
-- Discussion of novel siRNA therapeutics targeting other oncology indications
Presentation Title: GalAhead(TM) Therapeutic Platform and Programs
Presenter: Dr. Jack Wei, Senior Director, Sirnaomics
Time/Date: 16:30 GMT on Thursday, September 22, 2022
Presentation Topics:
-- Introduction to GalAhead(TM), Sirnaomics' GalNAc-RNAi therapeutic platform
-- Miniaturized RNAi (mxRNA) as a key technological component of the platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead(TM)-based programs
For more information about Sirnaomics' presentation, please visit the event website at https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery.
About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.
CONTACT:
Investor Relations:
Nigel Yip, MBA
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com
US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com
Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com
Topic: Press release summary
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Tong Ren Tang Healthcare (02667.HK), Targets Hong Kong IPO
June 26, 2026 21:16 HKT/SGT
|
|
|
IP Go-Global Business Matching Session held in Guangzhou
June 26, 2026 19:36 HKT/SGT
|
|
|
Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China
June 26, 2026 19:33 HKT/SGT
|
|
|
JCB and PNB Launch New Platinum Credit Card, Empowering Consumers with Greater Value and Lifestyle Benefits
Friday, June 26, 2026 5:00:00 PM
|
|
|
KEYTOP PARKING INC. Officially Lists on the Main Board of Hong Kong Stock Exchange
June 26, 2026 10:55 HKT/SGT
|
|
|
XJTLU Strengthens Presence in Indonesia, Offers Double Degrees and Global Career Pathways 
June 26, 2026 10:00 HKT/SGT
|
|
|
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies
June 26, 2026 09:00 HKT/SGT
|
|
|
GIC Discloses Third Change in Shareholding in Ascletis Pharma Inc. -B (01672.HK) This Year: Further Increases Stake by Over 10 Million Shares, Raising Holding from 7.00% to 8.36%
June 26, 2026 08:37 HKT/SGT
|
|
|
GA-ASI Adapts Ground Control Station to Fly MQ-9B
June 25, 2026 22:00 HKT/SGT
|
|
|
Pacific Avenue Capital Partners Announces Investment Committee Appointment, New AI Initiative, and Team Expansion
June 25, 2026 21:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
